MindBio Therapeutics Appoints Haywood Securities for Strategic Investment Advisory

VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), a leading biopharmaceutical company in psychiatric medicine development, has announced the appointment of Haywood Securities Inc. as its strategic advisor. Haywood will assist MindBio in securing potential strategic investments and transactions.

The agreement includes fees paid in Warrants, with up to 7,500,000 Warrants issued for a commitment of six months. Customary success fees apply upon the successful completion of a transaction.

MindBio has multiple Phase 2B clinical trials underway, which include regulatory approval for take-home use of their lead candidate, MB22001. The drug has shown promising results in depression trials.

MindBio's focus is on microdosing psychedelic medicines as an effective and affordable treatment for mental health conditions. Current trials include studies for depression and cancer, with a recent addition for PMS/PMDD.

Justin Hanka, CEO of MindBio, expressed enthusiasm for the partnership with Haywood to lead their strategic investment initiatives.